1. Home
  2. News Archive

More News

reVision Licenses Stargardt Treatment Candidate from Cornell U.

reVision Therapeutics, of Ridgewood, New Jersey, announced Sept. 1 that it had signed an exclusive license agreement with Cornell University for the development and commercialization of Cornell’s p...

Translational Imaging Innovations Gets $1.5 Million Grant for Eye Imaging Analysis Software

Translational Imaging Innovations (TII) has been awarded a $1.5 million Direct-to-Phase II Small Business Innovation Research grant from the National Eye Institute of the National Institutes of Hea...

Lineage Receives $24.6 Million Payment from Juvenescence

Lineage Cell Therapeutics announced Aug. 31 that it had received $24.6 million in cash from Juvenescence, representing principal and interest due under a convertible promissory note. The note was i...

Alimera Sciences Begins Phase IV Study of Iluvien as First-Line DME Treatment

Alimera Sciences, of Alpharetta, Georgia, announced Sept. 1 that it had enrolled the first patient in a Phase IV trial to evaluate Iluvien as a first-line treatment in early diabetic macular edema ...

Oxurion Doses First Patient in Phase II Study of THR-149 for DME

Belgian company Oxurion announced Sept. 1 that the first patient had been dosed in its two-part Phase II study evaluating THR-149 for the treatment of DME. THR-149 is a plasma kallikrein inhibitor ...

​Oculis Establishes US Presence in Boston

Oculis, of Lausanne, Switzerland, announced Sept. 1 that it had established a US entity, Oculis Inc., in Boston. The biopharmaceutical company also announced the appointment of Sylvia Cheung as chi...

Smith & Nephew Launches ARIA Platform to Connect Patients With Providers

Smith & Nephew announced Aug. 25 that it has launched ARIA, a care management platform and application powered by the firm’s Real Intelligence ecosystem and its Positive Connections ASC program. AR...

FDA Approves Recordati’s Cystadrops for Ophthalmic Symptoms of Cystinosis

Italy-based Recordati Rare Diseases reported Aug. 25 that the US FDA had approved the company’s Cystadrops (cysteamine ophthalmic solution) 0.37% as a treatment for corneal cystine crystal deposits...

Gyroscope Gains US FDA Clearance for Orbit Subretinal Delivery System

Gyroscope Therapeutics, of London, announced Aug. 25 that the US FDA had granted 510(k) clearance for the Orbit Subretinal Delivery System (SDS). The Orbit SDS is indicated for microinjection into ...

Scientists in India Use Aspirin-Based Nanorods in Eye Drops to Prevent Cataracts

India’s government announced Aug. 2 that scientists from its Institute of Nano Science & Technology (INST) had effectively used aspirin-based nanorods in eye drops to prevent cataract formation. Th...

PDL Prepares for Potential Spinoff of LENSAR

PDL BioPharma, parent of device maker LENSAR, announced Aug. 26 that it had filed paperwork with the US Securities and Exchange Commission for a potential spin-off of LENSAR to PDL’s stockholders. ...

US FDA Accepts Regenxbio’s IND for Phase II Trial of RGX-314 for DR

Regenxbio announced Aug. 25 that the US FDA had accepted its investigational new drug (IND) application to evaluate the suprachoroidal delivery of its gene therapy RGX-314 in patients with diabetic...

Zeiss IOLMaster 700 Software Update Adds Central Topography 

Carl Zeiss Meditec announced Aug. 27 that its IOLMaster 700 had been enhanced with new software, including central topography for more insights on corneal shape. The update also features Zeiss EQ M...

Outlook’s Lytenava Shows Safety, Efficacy Consistent with Other Bevacizumab Studies

Outlook Therapeutics announced topline results Aug. 26 that the company said demonstrated safety and efficacy and positive proof-of-concept for ONS-5010 (bevacizumab-vikg) for the treatment of wet ...

EyePoint Receives $9.5 Million from Ocumension Under Expanded License Agreements

EyePoint and Ocumension announced Aug. 20 that they had expanded their exclusive license agreements for the development and commercialization of Yutiq and Dexycu in certain Asian markets. Dexycu is...

Nanodropper Awarded a Phase II SBIR Contract with US Air Force

Nanodropper, which offers a first-of-its-kind bottle adaptor that reduces eye drop size, has received a Phase II Small Business Innovation Research (SBIR) contract with the US Air Force, the compan...

Tarsus Names Aziz Mottiwala as Chief Commercial Officer

Tarsus Pharmaceuticals reported Aug. 11 that Aziz Mottiwala had been appointed chief commercial officer. The Irvine, California, company is developing therapeutic candidates to address large market...

iVeena Closes Series B Financing to Advance Multiple Programs in Clinical Development

iVeena, of Salt Lake City, announced Aug. 25 that it had completed a Series B preferred stock bridge round and received an SBIR Phase II grant award from the National Eye Institute. The company sai...

LensGen Closes $10 Million Financing, Adds Mazzo to Board

LensGen announced Aug. 20 the closing of $10 million in financing and the addition of Jim Mazzo to its board. The financing was led by the venture arm of Hoya Group and is part of a larger Series B...

Bausch Health to Spin Out Bausch + Lomb as Separate Public Company

Canada-headquartered Bausch Health Companies announced Aug. 6 that it plans to spin off Bausch + Lomb into a separate publicly traded company. The new entity will be called Bausch + Lomb—NewCo and ...

ASRS Packs Meeting With Quick Paper Summaries, Q&As

The American Society of Retina Specialists’ 2020 virtual conference moved at a pace more typical of a speed dating event. The online scientific meeting fit 137 papers, three take-home sessions, two...

ASRS Participants Highlight Latest Technologies in Retinal Surgery

Many sessions at the ASRS meeting focused on how innovation is improving surgery. Richard Rosen, MD, provided an update during the Technology Symposium on the promise of robotics in ophthalmology. ...

Ophthalmologists Seek to Update Old FDA Guidance Excluding Gay Men from Cornea Donation

A tissue donation policy that the US FDA instituted during the AIDS crisis is resulting in viable corneas going unused. Many ophthalmologists say it is time to update the regulation. FDA guidance p...

Octane Uses Sophisticated Virtual Platform for Well-Attended Ophthalmology Summit

Octane raised the bar for virtual meetings with its 2020 Ophthalmology Technology Summit, held Aug. 6-8. The Southern California-based accelerator used its own app and online platform that integrat...

VSY Launches Dry-Packed IOL Designed to be Glistening Free

VSY Biotechnology launched its Enova intraocular lens on July 22. The Germany-based company said Enova is designed to be the first glistening-free hydrophobic acrylic IOL that does not require pre-...

BVI Launches IPure, its First IOL in the US

BVI announced Aug. 17 that it had launched the IPure intraocular lens (IOL) in the US. The IPure is a preloaded aspheric monofocal IOL available in both a one-piece and three-piece design. BVI said...

EyePoint, ImprimisRx Join Forces to Promote Dexycu Intracameral Steroid in the US

EyePoint Pharmaceuticals and ImprimisRx announced Aug. 4 that they had formed a commercial alliance for the joint promotion in the US of Dexycu (dexamethasone intraocular suspension) 9% for the tre...

Innovations Will Propel OCT Market to $549 Million in 2020

Recent innovations in optical coherence tomography (OCT) technology—such as systems that are combined with fundus imagers—and software advancements, including OCT angiography, are growing in popula...

More Effective Glaucoma Devices Will Lead to Increased Use Through 2025

Expanding use of surgical devices in patients with all stages of glaucoma will increase the role of surgery in the glaucoma treatment paradigm over the next five years. There are four FDA-approved ...

2020 Proves to be Tough Year for Competitors of Eylea

The year 2020 has been tough on retinal pharmaceutical companies. Lucentis sales were down in the first half of the year: 19 percent in the US and 15 percent outside the US (on a constant currency ...

Eyenuk Gains FDA Clearance for EyeArt Autonomous AI for Screening of DR

Eyenuk announced Aug. 5 that it had received 510(k) clearance from the US FDA to market its EyeArt autonomous AI system for diabetic retinopathy (DR). Eyenuk, of Woodland Hills, California, says it...

UVC Treatment for Corneal Infections Wins 2020 Winning Pitch Challenge

Sunil Shah, MD, of the UK, won the 2020 Winning Pitch Challenge with a UVC device he co-invented to treat corneal infections with ultraviolet light. He represented Photon Therapeutics and its team ...

Emerging Companies Pursuing Ophthalmic Indications, August 2020

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease. Company Location About Ashvattha Therapeutics Redwood City, California The company says its ...

US FDA Grants Clearance to Zeiss’ xPORT 304, Adding Aspiration to Dissection Use

The US FDA on July 31 granted 510(k) clearance to Carl Zeiss Meditec’s xPORT 304 (miCOR) System for cataract surgery. The system adds aspiration functionality to the miLOOP lens fragmentation devic...

AAO, ASCRS Ask Congress to Prevent 6 Percent Reduction in Ophthalmologists’ Fees

The American Academy of Ophthalmology (AAO) and American Society of Cataract and Refractive Surgery (ASCRS) have asked Congress to prevent the latest proposed cuts in Medicare reimbursement to opht...

Market Scope Weekly Ophthalmic Surgeon and Industry Polls for August 2020

Omeros Leads Latest Fundraising Efforts with $297.4 Million in Two Public Offerings

Omeros led recent fundraising efforts by ophthalmic companies, raising $297.4 million in two underwritten public offerings. Funding for the past four weeks totaled $630.7 million. Date Company Amou...

August 2020 Ophthalmic News Briefs

French laser company Lumibird announced Aug. 3 that it had acquired EssMed, one of its distribution companies. EssMed operates in Sweden, Finland, and Norway, with revenue of around €2 million (US ...

Q2-2020 Earnings: Alcon, Omeros

Alcon reported Aug. 19 that its Q2-2020 sales were $1.2 billion, a decrease of 36 percent (34 percent cc) from $1.9 billion in Q2-2019. Sales for the first half of 2020 were $3.0 billion, a drop of...

BVI Launches IPure, its First Intraocular Lens in the US

BVI announced Aug. 17 that it had launched the IPure intraocular lens (IOL) in the US. The IPure is a pre-loaded aspheric monofocal IOL available in both a one-piece and three-piece design. BVI sai...

US FDA Approves Genentech’s Enspryng for NMOSD

Genentech, a member of the Roche Group, announced Aug. 15 that the US FDA had approved Enspryng (satralizumab-mwge) as the first subcutaneous treatment for adults with anti-aquaporin-4 (AQP4) antib...

US FDA Grants Clearance to Zeiss’ xPORT 304, Adding Aspiration to Dissection Use

The US FDA on July 31 granted 510(k) clearance to Carl Zeiss Meditec’s xPORT 304 (miCOR) System for cataract surgery. The system adds aspiration functionality to the miLOOP lens fragmentation devic...

Doctor Laments Loss of TrueTear, Blames High Manufacturing Costs

Darrell E. White, MD, in a blog post Aug. 17 on Healio, said the demise of AbbVie/Allergan’s TrueTear for dry eye disease stemmed from the fact that the device was too expensive to manufacture, put...

Eyenovia Prices $12 Million Public Offering

Eyenovia, of New York, announced Aug. 19 that it had priced an underwritten public offering of 3.3 million shares of its common stock at $3.60 per share. The company granted underwriters a 30-day o...

Tom Frinzi Joins CorneaGen Board as Executive Chair

CorneaGen announced Aug. 13 that industry veteran Tom Frinzi had joined the company’s board as executive chair. Former board chair Bill Link, PhD, will remain on the board, CorneaGen said. The Seat...

4D Molecular Doses First Patient in Trial of Gene Therapy Candidate for X-Linked RP

4D Molecular Therapeutics (4DMT) announced Aug. 19 that the first patient had been dosed in a Phase I/II clinical trial of its gene therapy candidate 4D-125 for X-linked retinitis pigmentosa (XLRP)...

Gyroscope Doses First Patient in Phase II Trial of Gene Therapy for Dry AMD

Gyroscope Therapeutics, of London, announced Aug. 13 that the first patient had been dosed in a Phase II trial evaluating its investigational gene therapy, GT005, for the treatment of geographic at...

Trefoil Begins First Clinical Trial of Regenerative Treatment for Corneal Endothelial Dystrophies

Trefoil Therapeutics announced Aug. 19 that it had initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of corneal endothelial dys...

Procedure Volumes Collapse in Pandemic-Affected Q2-2020

US orthopedic surgeons responding to Market Scope’s Q2-2020 surveys said orthopedic procedures declined 30.3 percent in Q2 compared with the same quarter last year. Our surveys covered knee arthrop...

Orthopedic Deals Experience Huge Summer Spike

Fifteen noteworthy deals took place from June 23 through July 28. This is a huge increase from six deals in the previous month. The largest disclosed transaction was Medtronic’s acquisition of Medi...

Want to Read Locked Articles?

Register A Corporate Account

A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.

Select one or more
Select one or more

Market Scope

13421 Manchester Road, Suite 201 | St. Louis, MO 63131 | Phone: 314-835-0600 | Email: info@market-scope.com

©2020 Market Scope, LLC. All Rights reserved.